Literature DB >> 35788731

ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications.

Sarah M Belcher1, Emily Mackler2, Benyam Muluneh3, Pamela K Ginex4, Mary K Anderson5, Elizabeth Bettencourt6, Ryan K DasGupta7, Jennifer Elliott8, Erica Hall9, Michelle Karlin10, Diana Kostoff7, Victoria K Marshall11, Vanessa E Millisor12, Maegan Molnar13, Susan M Schneider14, Janelle Tipton15, Susan Yackzan16, Kristine B LeFebvre4, Kapeena Sivakumaran17, Haya Waseem17, Rebecca L Morgan18.   

Abstract

PURPOSE: This evidence-based guideline intends to support patients, clinicians, and others regarding interventions and processes to support patient adherence to oral anticancer medications (OAMs). METHODOLOGIC APPROACH: A panel of healthcare professionals and patient representatives developed a clinical practice guideline to support patients taking OAMs. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology and criteria for trustworthy guidelines were followed. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. A quantitative or narrative synthesis of the evidence was completed. Certainty of the evidence was assessed using GRADE.
FINDINGS: The panel agreed on recommendations and suggested an adherence risk assessment, education addressing adherence, ongoing assessment, proactive follow-up, coaching, and motivational interviewing in addition to usual care. The panel suggested the implementation of a structured OAM program. IMPLICATIONS FOR NURSING: As cancer treatment shifts from clinic to home settings, interventions and programs to support patients on OAMs are needed.

Entities:  

Keywords:  medication adherence; nursing; oncology care; oral anticancer medication; scoping review

Mesh:

Year:  2022        PMID: 35788731      PMCID: PMC9303042          DOI: 10.1188/22.ONF.279-295

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   1.803


  71 in total

1.  RoB 2: a revised tool for assessing risk of bias in randomised trials.

Authors:  Jonathan A C Sterne; Jelena Savović; Matthew J Page; Roy G Elbers; Natalie S Blencowe; Isabelle Boutron; Christopher J Cates; Hung-Yuan Cheng; Mark S Corbett; Sandra M Eldridge; Jonathan R Emberson; Miguel A Hernán; Sally Hopewell; Asbjørn Hróbjartsson; Daniela R Junqueira; Peter Jüni; Jamie J Kirkham; Toby Lasserson; Tianjing Li; Alexandra McAleenan; Barnaby C Reeves; Sasha Shepperd; Ian Shrier; Lesley A Stewart; Kate Tilling; Ian R White; Penny F Whiting; Julian P T Higgins
Journal:  BMJ       Date:  2019-08-28

2.  Proof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled Trial.

Authors:  Sandra L Spoelstra; Charles W Given; Alla Sikorskii; Constantinos K Coursaris; Atreyee Majumder; Tracy DeKoekkoek; Monica Schueller; Barbara A Given
Journal:  Telemed J E Health       Date:  2015-12-30       Impact factor: 3.536

3.  Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence.

Authors:  Mélanie Dos Santos; M Lange; R Gervais; B Clarisse; A Capel; M Barillet; J M Grellard; N Heutte; I Licaj; F Joly
Journal:  Support Care Cancer       Date:  2019-01-28       Impact factor: 3.603

4.  Interventions to Support Adherence to Oral Anticancer Medications: Systematic Review and Meta-Analysis.

Authors:  Haya Waseem; Pamela K Ginex; Kapeena Sivakumaran; Gina M DeGennaro; Sarah Lagler-Clark; Kristine B LeFebvre; Nicole Palmer; Tejanth Pasumarthi; Paula Rieger; Kelli Thoele; Rebecca L Morgan
Journal:  Oncol Nurs Forum       Date:  2022-06-17       Impact factor: 1.803

Review 5.  Domains of Structured Oral Anticancer Medication Programs: A Scoping Review.

Authors:  Kapeena Sivakumaran; Pamela K Ginex; Haya Waseem; Sarah M Belcher; Sarah Lagler-Clark; Kristine B LeFebvre; Nicole Palmer; Tejanth Pasumarthi; Rebecca L Morgan
Journal:  Oncol Nurs Forum       Date:  2022-06-17       Impact factor: 1.803

6.  Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.

Authors:  Vittorio Gebbia; Massimo Bellavia; Giuseppe Luigi Banna; Paolo Russo; Francesco Ferraù; Paolo Tralongo; Nicolò Borsellino
Journal:  Clin Lung Cancer       Date:  2013-01-10       Impact factor: 4.785

7.  Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.

Authors:  Miryam Yusufov; Margo Nathan; Aleta Wiley; Julia Russell; Ann Partridge; Hadine Joffe
Journal:  Breast Cancer Res Treat       Date:  2020-09-12       Impact factor: 4.872

8.  Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: A mixed-method randomised controlled trial.

Authors:  Hiroko Komatsu; Kaori Yagasaki; Takuhiro Yamaguchi; Ayako Mori; Hiromi Kawano; Noriko Minamoto; Orie Honma; Kenji Tamura
Journal:  Eur J Oncol Nurs       Date:  2020-06-14       Impact factor: 2.398

Review 9.  The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.

Authors:  Gilly Arthurs; Janice Simpson; Andrea Brown; Ohnma Kyaw; Sharon Shyrier; Catherine M Concert
Journal:  JBI Database System Rev Implement Rep       Date:  2015-06-12

10.  A Pharmacist-Led Oral Chemotherapy Program's Impact on Chronic Myeloid Leukemia Patient Satisfaction, Adherence, and Outcomes.

Authors:  Taylor Dennison; Allison M Deal; Matthew Foster; John Valgus; Benyam Muluneh
Journal:  J Adv Pract Oncol       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.